PT  - JOURNAL ARTICLE
AU  - Johannes Leiner
AU  - Vincent Pellissier
AU  - Sven Hohenstein
AU  - Sebastian König
AU  - Ekkehard Schuler
AU  - Robert Möller
AU  - Irit Nachtigall
AU  - Marzia Bonsignore
AU  - Gerhard Hindricks
AU  - Ralf Kuhlen
AU  - Andreas Bollmann
TI  - Characteristics and outcomes of COVID-19 patients during B.1.1.529 (Omicron) dominance compared to B.1.617.2 (Delta) in 89 German hospitals
AID  - 10.1101/2022.04.09.22273420
DP  - 2022 Jan 01
TA  - medRxiv
PG  - 2022.04.09.22273420
4099  - http://medrxiv.org/content/early/2022/04/13/2022.04.09.22273420.short
4100  - http://medrxiv.org/content/early/2022/04/13/2022.04.09.22273420.full
AB  - Background The SARS-CoV-2 variant of concern B.1.1.529 (Omicron) was first described in November 2021 and soon became the dominant variant worldwide. Existing data suggests a reduced disease severity in comparison to B.1.617.2 (Delta). Differences in characteristics and in-hospital outcomes of patients with COVID-19 in Germany during the Omicron period compared to Delta are not thoroughly studied. Surveillance for severe acute respiratory infections (SARI) represents an integral part of infectious disease control in Germany.Methods Administrative data from 89 German Helios hospitals was retrospectively analysed. Laboratory-confirmed SARS-CoV-2 infections were identified by ICD-10-code U07.1 and SARI cases by ICD-10-codes J09-J22. COVID-19 cases were stratified by concomitant SARI. A nine-week observational period between December 6, 2021 and February 6, 2022 was defined and divided into three phases with respect to the dominating virus variant (Delta, Delta to Omicron transition, Omicron). Regression analyses adjusted for age, gender and Elixhauser comorbidities were applied to assess in-hospital patient outcomes.Results A total cohort of 4,494 inpatients was analysed. Patients in the Omicron dominance period were younger (mean age 61.6 vs. 47.8; p<0.01), more likely to be female (54.7% vs. 47.5%; p<0.01) and characterized by a lower comorbidity burden (mean Elixhauser comorbidity index 8.2 vs. 5.4; p<0.01). Comparing Delta and Omicron periods, patients were at significantly lower risk for intensive care treatment (adjusted odds ratio 0.64 [0.51-0.8]; p<0.001), mechanical ventilation (adjusted odds ratio 0.38 [0.28-0.51]; p<0.001), and in-hospital mortality (adjusted odds ratio 0.42 [0.32-0.56]; p<0.001). This also applied to the separate COVID-SARI group. During the Delta to Omicron transition, case numbers of COVID-19 without SARI exceeded COVID-SARI.Conclusion Patient characteristics and outcomes differ during the Omicron dominance period as compared to Delta suggesting a reduced disease severity with Omicron infections. SARI surveillance might play a crucial role in assessing disease severity of future SARS-CoV-2 variants.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study did not receive any fundingAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Local ethics committee of the University of Leipzig (vote: AZ490/20-ek) and the Helios Kliniken GmbH data protection authority approved data use for this study.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data that support the findings of this study are not publicly available as they contain information that could compromise the privacy of research participants but are available from the corresponding author, Mr. Johannes Leiner (Johannes.leiner@helios-gesundheit.de) upon reasonable request.CIConfidence intervalCOVID-19Coronavirus disease 2019ECDCEuropean Centre for Disease Prevention and ControlGLMMGeneralized linear mixed modelsICD-10-GMInternational Statistical Classification of Diseases and Related Health Problems Version 10, German ModificationICUIntensive care unitLMMLinear mixed modelsOPSOperation and Procedure Classification SystemRKIRobert-Koch-InstituteSARISevere acute respiratory infectionSARI+COVID-19 with SARISARI-COVID-19 without SARISARS-CoV-2Severe acute respiratory syndrome coronavirus 2VoCVariant of ConcernWHOWorld Health Organization